Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

FATE Fate Therapeutics, Inc.
$1.11 -2.68% -0.03
Notify me if price changes either direction
Interactive Brokers Logotype

Buy FATE stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades
Loading

Key Stats

Market cap. 125.7M
Enterprise value -6980436
Trailing PE -0.66768294427453
Forward PE -0.9899107
PEG Ratio 0.020544090593062
Enterprise to EBITDA 0.048
Enterprise to revenue -0.978
Price to book MRQ 0.5643174
Price to sales TTM 18.506147

Financials

Fiscal Year Ends 2024-12-31
Most Recent Quarter (MRQ) 2025-09-30
Revenue (TTM) 7.1M
EBITDA -145343008
Diluted EPS TTM -1.33
Total Cash (MRQ) 215.4M
Current ratio (MRQ) 7.871
Operating Cash Flow (TTM) -110569000

FATE trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent FATE News

Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.